Veraxa Biotech AG - Post de-SPAC
VRXAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002079109
In the last 90 days, Veraxa Biotech AG - Post de-SPAC insiders filed 2 open-market purchases and 0 sales; 27 institutions reported holding it in 13F filings for Q2 2026, worth $992.5K in total; no superinvestor holds it.
Other share classesVRXA
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Veraxa Biotech AG - Post de-SPAC insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 2 filings
- 2 insiders, $82.7K in total
- Open-market sells
- 0 filings
- Insiders trading
- 2
- Net value
- +$82.7K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Veraxa Biotech AG - Post de-SPAC, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Baumann Oliver Rolf | Director | 5,773,618Indirect | Aug 31, 2026 | 1 |
| Antz Christoph Rudiger | Chief Executive Officer | 5,000 | Aug 31, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 (view filing)4:10 PM ET | Aug 27 | 4 days | Baumann Oliver RolfDirector | PPurchase | +50.0K | $1.50 | +$75.0K | +0.9%5.77M after | |
| Aug 31, 2026 (view filing)4:10 PM ET | Aug 27 | 4 days | Antz Christoph RudigerChief Executive Officer | PPurchase | +5.00K | $1.53 | +$7.65K | New position5.00K after |